NLS Pharmaceutics, which is developing controlled-release formulations of approved drugs for ADHD and narcolepsy, filed on Tuesday with the SEC to raise up to $40 million in an initial public offering ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results